1 week Ago By Defense World Staff
Geode Capital Management LLC boosted its stake in AnaptysBio, Inc. ( NASDAQ:ANAB – Free Report ) by 4.6% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission.
The firm owned 486,597 shares of the biotechnology company’s stock after acquiring an additional 21,196 shares during the period. Geode Capital Management LLC owned 1.60% of AnaptysBio worth $6,444,000 as of its most recent SEC filing.
A number of other hedge funds also recently added to or reduced their stakes in the stock. JPMorgan Chase & Co. lifted its holdings in shares of AnaptysBio by 191.
4% during the third quarter. JPMorgan Chase & Co. now owns 33,744 shares of the biotechnology company’s stock worth $1,130,000 after purchasing an additional 22,164 shares during the period.
Victory Capital Management Inc. lifted its stake in shares of AnaptysBio by 41.0% in the 4th quarter.
Victory Capital Management Inc. now owns 334,450 shares of the biotechnology company’s stock worth $4,428,000 after acquiring an additional 97,200 shares during the period. Y Intercept Hong Kong Ltd purchased a new stake in shares of AnaptysBio in the fourth quarter valued at about $311,000.
Vanguard Group Inc. boosted its holdings in shares of AnaptysBio by 8.4% in the fourth quarter.
Vanguard Group Inc. now owns 1,843,740 shares of the biotechnology company’s stock valued at $24,411,000 after acquiring an additional 143,584 shares in the last quarter. Finally, AlphaQuest LLC increased its stake in shares of AnaptysBio by 1,891.
5% during the fourth quarter. AlphaQuest LLC now owns 4,461 shares of the biotechnology company’s stock worth $59,000 after acquiring an additional 4,237 shares during the period. Analyst Upgrades and Downgrades A number of equities research analysts have weighed in on the company.
Johnson Rice reaffirmed a “buy” rating on shares of AnaptysBio in a report on Wednesday, March 26th. Wolfe Research began coverage on AnaptysBio in a report on Tuesday, February 4th. They set an “outperform” rating and a $25.
00 price objective on the stock. Guggenheim reissued a “buy” rating on shares of AnaptysBio in a report on Monday, March 3rd. HC Wainwright reiterated a “neutral” rating and issued a $22.
00 price target on shares of AnaptysBio in a report on Tuesday, March 4th. Finally, JPMorgan Chase & Co. boosted their price objective on shares of AnaptysBio from $36.
00 to $42.00 and gave the stock an “overweight” rating in a report on Wednesday, March 5th. Four equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company.
According to MarketBeat.com, AnaptysBio currently has an average rating of “Moderate Buy” and an average price target of $33.63.
AnaptysBio Trading Up 0.4 % Shares of NASDAQ ANAB opened at $20.70 on Friday.
The stock has a market cap of $634.81 million, a price-to-earnings ratio of -3.40 and a beta of -0.
09. The company’s 50-day moving average price is $17.92 and its 200 day moving average price is $19.
62. AnaptysBio, Inc. has a 52 week low of $12.
21 and a 52 week high of $41.31. AnaptysBio ( NASDAQ:ANAB – Get Free Report ) last issued its quarterly earnings data on Thursday, February 27th.
The biotechnology company reported ($0.72) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.61) by $0.
89. AnaptysBio had a negative net margin of 289.75% and a negative return on equity of 287.
94%. The business had revenue of $43.11 million during the quarter, compared to analysts’ expectations of $10.
17 million. As a group, research analysts expect that AnaptysBio, Inc. will post -6.
08 earnings per share for the current year. AnaptysBio declared that its Board of Directors has initiated a stock repurchase plan on Monday, March 24th that permits the company to buyback $75.00 million in outstanding shares.
This buyback authorization permits the biotechnology company to reacquire up to 13.1% of its shares through open market purchases. Shares buyback plans are typically a sign that the company’s board believes its stock is undervalued.
AnaptysBio Company Profile ( Free Report ) AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. Featured Stories Five stocks we like better than AnaptysBio How to Buy Cheap Stocks Step by Step Short Sellers Gave Up on These 3 Names Recently Biggest Stock Losers – Today’s Biggest Percentage Decliners 3 Boring Stocks Outperforming the Market This Year Stock Trading Terms – Stock Terms Every Investor Needs to Know If You Wanted To Buy AbbVie and Didn’t, There’s Still Time To Buy Receive News & Ratings for AnaptysBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio and related companies with MarketBeat.
com's FREE daily email newsletter ..
